La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CSPC Pharmaceutical Group Crescita futura

Future criteri di controllo 1/6

CSPC Pharmaceutical Group prevede che gli utili e i ricavi cresceranno rispettivamente di 4.3% e 5.2% all'anno. Si prevede che l'EPS crescerà di 4.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 15.8% in 3 anni.

Informazioni chiave

4.1%

Tasso di crescita degli utili

4.1%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	11.2%
Tasso di crescita dei ricavi	5.3%
Rendimento futuro del capitale proprio	15.8%
Copertura analitica	Good
Ultimo aggiornamento	21 Aug 2024

Aggiornamenti recenti sulla crescita futura

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29

Recent updates

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Dec 26

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price

Oct 18

CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt

Sep 15

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10

Aug 26

Previsioni di crescita degli utili e dei ricavi

SEHK:1093 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	40,180	7,581	6,441	N/A	23
12/31/2025	37,150	6,966	6,079	N/A	26
12/31/2024	31,766	6,089	6,385	N/A	2
3/31/2024	32,380	6,057	N/A	N/A	N/A
12/31/2023	31,450	5,873	2,290	4,179	N/A
9/30/2023	31,306	6,118	N/A	N/A	N/A
6/30/2023	31,407	6,092	1,985	4,690	N/A
3/31/2023	31,116	6,116	N/A	N/A	N/A
12/31/2022	30,937	6,091	4,922	7,627	N/A
9/30/2022	30,721	5,738	N/A	N/A	N/A
6/30/2022	29,655	5,509	4,098	6,151	N/A
3/31/2022	29,007	5,538	N/A	N/A	N/A
12/31/2021	27,867	5,605	2,887	4,637	N/A
9/30/2021	26,369	5,977	N/A	N/A	N/A
6/30/2021	26,175	5,908	5,865	7,053	N/A
3/31/2021	25,551	5,472	N/A	N/A	N/A
12/31/2020	24,942	5,160	5,362	6,740	N/A
9/30/2020	24,558	4,421	N/A	N/A	N/A
6/30/2020	23,515	4,150	3,129	4,614	N/A
3/31/2020	22,735	3,922	N/A	N/A	N/A
12/31/2019	22,103	3,714	1,835	3,784	N/A
9/30/2019	21,335	3,625	N/A	N/A	N/A
6/30/2019	20,135	3,454	1,370	3,743	N/A
3/31/2019	18,835	3,294	N/A	N/A	N/A
12/31/2018	17,717	3,081	1,922	3,795	N/A
9/30/2018	16,877	2,905	N/A	N/A	N/A
6/30/2018	15,729	2,734	1,827	3,352	N/A
3/31/2018	13,959	2,443	N/A	N/A	N/A
12/31/2017	12,877	2,307	N/A	2,738	N/A
9/30/2017	12,203	2,195	N/A	N/A	N/A
6/30/2017	11,659	2,068	N/A	2,811	N/A
3/31/2017	11,383	1,979	N/A	N/A	N/A
12/31/2016	11,075	1,881	N/A	2,611	N/A
9/30/2016	10,439	1,711	N/A	N/A	N/A
6/30/2016	10,118	1,607	N/A	2,147	N/A
3/31/2016	9,656	1,473	N/A	N/A	N/A
12/31/2015	9,545	1,395	N/A	1,884	N/A
9/30/2015	9,284	1,305	N/A	N/A	N/A
6/30/2015	9,072	1,192	N/A	1,192	N/A
3/31/2015	8,919	1,126	N/A	N/A	N/A
12/31/2014	8,762	1,015	N/A	1,445	N/A
9/30/2014	8,423	896	N/A	N/A	N/A
6/30/2014	8,197	849	N/A	1,059	N/A
3/31/2014	8,001	814	N/A	N/A	N/A
12/31/2013	7,768	760	N/A	636	N/A
9/30/2013	7,345	1,967	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 1093 ( 4.3% all'anno) è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 1093 ( 4.3% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 1093 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 1093 ( 5.2% all'anno) crescerà più lentamente rispetto al mercato Hong Kong ( 7.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 1093 ( 5.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 1093 sarà basso tra 3 anni ( 15.8 %).

CSPC Pharmaceutical Group Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

Recent updates

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of HK$0.14 per share

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Executive Chairman exercised options to buy HK$52m worth of stock.

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

Investor sentiment improves as stock rises 19%

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.11 per share at 3.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Executive Chairman recently bought HK$13m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S